Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials-Reference-Cited by-同舟云学术

Increasing Access to FDA Inspection Reports on Irregularities and Misconduct in Clinical Trials

Published:2020-05-19 Issue:19 Volume:323 Page:1903
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Dal-Ré Rafael¹,Kesselheim Aaron S.²,Bourgeois Florence T.³⁴

Affiliation:

1. Epidemiology Unit, Health Research Institute─Fundación Jimenez Díaz, University Hospital, Universidad Autónoma de Madrid, Madrid, Spain

2. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

3. Computational Health Informatics Program (CHIP), Boston Children’s Hospital, Boston, Massachusetts

4. Department of Pediatrics, Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2765251/jama_dalr_2020_vp_200017.pdf

Reference7 articles.

1. Research misconduct identified by the US Food and Drug Administration: out of sight, out of mind, out of the peer-reviewed literature.;Seife;JAMA Intern Med,2015

2. Apixaban versus warfarin in patients with atrial fibrillation.;Granger;N Engl J Med,2011

3. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.;Turpie;Lancet,2009

4. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses: the example of the apixaban trials.;Garmendia;JAMA Intern Med,2019

5. Regarding “Eteplirsen for the treatment of Duchenne muscular dystrophy.”;Unger;Ann Neurol,2017

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost and availability of novel cell and gene therapies;EMBO reports;2023-01-02

2. Institutional Responsibilities for Research Integrity;Reconstructing Research Integrity;2023

3. FDA oversight of clinical trials is “grossly inadequate,” say experts;BMJ;2022-11-16

4. Fraud and retraction in perioperative medicine publications: what we learned and what can be implemented to prevent future recurrence;Journal of Medical Ethics;2021-05-14

5. The Big Data Regulator, Rebooted: Why and How the FDA Can and Should Disclose Confidential Data on Prescription Drugs and Vaccines;CALIF LAW REV;2021